936 research outputs found
Differential effects of theta/beta and SMR neurofeedback in ADHD on sleep onset latency
Recent studies suggest a role for sleep and sleep problems in the etiology of attention deficit hyperactivity disorder (ADHD) and a recent model about the working mechanism of sensori-motor rhythm (SMR) neurofeedback, proposed that this intervention normalizes sleep and thus improves ADHD symptoms such as inattention and hyperactivity/impulsivity. In this study we compared adult ADHD patients (N = 19) to a control group (N = 28) and investigated if differences existed in sleep parameters such as Sleep Onset Latency (SOL), Sleep Duration (DUR) and overall reported sleep problems (PSQI) and if there is an association between sleep-parameters and ADHD symptoms. Secondly, in 37 ADHD patients we investigated the effects of SMR and Theta/Beta (TBR) neurofeedback on ADHD symptoms and sleep parameters and if these sleep parameters may mediate treatment outcome to SMR and TBR neurofeedback. In this study we found a clear continuous relationship between self-reported sleep problems (PSQI) and inattention in adults with- and without-ADHD. TBR neurofeedback resulted in a small reduction of SOL, this change in SOL did not correlate with the change in ADHD symptoms and the reduction in SOL only happened in the last half of treatment, suggesting this is an effect of symptom improvement not specifically related to TBR neurofeedback. SMR neurofeedback specifically reduced the SOL and PSQI score, and the change in SOL and change in PSQI correlated strongly with the change in inattention, and the reduction in SOL was achieved in the first half of treatment, suggesting the reduction in SOL mediated treatment response to SMR neurofeedback. Clinically, TBR and SMR neurofeedback had similar effects on symptom reduction in ADHD (inattention and hyperactivity/impulsivity). These results suggest differential effects and different working mechanisms for TBR and SMR neurofeedback in the treatment of ADHD
Перевидання “Українських народних мелодій” К. Квітки: наукове значення і проблематика
The author of the article who has prepared the given anthology for republishing explains several important critical-textological principles of the methodology. Alongside with the collection never published Kvitka's "Commentary" is ready to be issued. The article speaks on the uniqueness of field and theoretical work done by a great ethnomusicologist Klyment Kvitka. The author presents the goal of the present edition of the anthology, which is to edit, to remove mistakes of the previous edition and to make a critical-textological analysis of the work. He illustrates Kvitka's specific features and approaches of ethnomusicological work as well
Motivational and control mechanisms underlying adolescent versus adult alcohol use
Increased motivation towards alcohol use and suboptimal behavioral control are suggested
to predispose adolescents to alcohol use disorders (AUDs). Paradoxically however, most adolescent
AUDs resolve over time without any formal intervention, suggesting adolescent resilience to AUDs.
Importantly, studies directly comparing adolescent and adult alcohol use are largely missing.
We therefore aimed to unravel the moderating role of age in the relation between alcohol use and
motivational and control-related cognitive processes in 45 adolescent drinkers compared to 45 adults.
We found that enhancement drinking motives and impulsivity related positively to alcohol use.
Although enhancement drinking motives and impulsivity were higher in adolescents, the strength of
the relation between these measures and alcohol use did not differ between age groups. None of
the alcohol use-related motivational measures (i.e., craving, attentional bias, and approach bias) and
behavioral control measures (i.e., interference control, risky decision making, and working-memory)
were associated with alcohol use or differed between age groups. These findings support the role of
impulsivity and affective sensitivity in adolescent drinking but question the moderating role of age
therein. The current study contributes towards understanding the role of age in the relation between
alcohol use and cognition
Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study
Updated clinical recommendations for the use of tibolone in Asian women
Tibolone, which is indicated for the relief of climacteric symptoms and the prevention of osteoporosis in postmenopausal women, has a tissue-specific mode of action different to that of conventional hormone replacement therapy (HRT). A large proportion of Asian postmenopausal women experience symptoms that most frequently include musculoskeletal pain, insomnia, forgetfulness, hot flushes and sexual dysfunction, and there is a need to address their specific requirements. Recent studies show that, in comparison to HRT, tibolone is as effective in alleviating menopausal symptoms and preventing bone loss, has a greater positive effect on sexual dysfunction and is associated with less vaginal bleeding, but it is rarely mentioned in guidelines for menopausal treatment. Levels of awareness amongst women about treatments for menopausal symptoms vary between Asian countries but, even in countries where awareness is high, HRT usage is much lower than in the West. To provide a practical approach to the use of tibolone in Asian postmenopausal women, a panel of experts in the management of menopause from 11 Asia Pacific countries has developed recommendations for its use, based on the evidence from clinical studies published since 2005. However, as much of the clinical data reviewed are from international studies, the recommendations and the treatment algorithm presented here are widely applicable
Effects of caffeine on cognitive and autonomic measures in heavy and light caffeine consumers
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women; A 2 year, placebo-controlled study
Currently raloxifene, a selective estrogen receptor modulator, is being investigated as a potential alternative for postmenopausal hormone replacement to prevent osteoporosis and cardiovascular disease. We compared the 2-year effects of raloxifene on a wide range of cardiovascular risk factors with those of placebo and conjugated equine estrogens (CEEs). Analyses were based on 56 hysterectomized but otherwise-healthy postmenopausal women aged 54.8±3.5 (mean±SD) years who entered this double- blind study and who were randomly assigned to raloxifene hydrochloride 60 mg/d (n = 15) or 150 mg/d (n= 13), placebo (n= 13), or CEEs 0.625 mg/d (n = 15). At baseline and after 6, 12, and 24 months of treatment, we assessed serum lipids, blood pressure, glucose metabolism, C-reactive protein, and various hemostatic parameters. Compared with placebo, both raloxifene and CEEs lowered the level of low density lipoprotein cholesterol by 0.53 to 0.79 mmol/L (all P<0.04) and lowered, at 24 months, the level of fibrinogen by 0.71 to 0.86 g/L (all P<0.05). The effects of raloxifene and CEEs did not differ significantly. In contrast to raloxifene, from 6 months on CEEs increased high density lipoprotein cholesterol by 0.25 to 0.29 mmol/L and reduced plasminogen activator inhibitor-1 antigen by 30.6 to 48.6 ng/mL (all P<0.02 versus both placebo and raloxifene). CEEs transiently increased C- reactive protein by 1.0 mg/L at 6 months (P<0.05 versus placebo) and- prothrombin-derived fragment F1 +2 by 0.79 nmol/L at 12 months (P<0.001 versus placebo). Finally, from 12 months on, CEEs increased triglycerides by 0.33 to 0.56 mmol/L (all P<0.05 versus both placebo and raloxifene). Our findings suggest that in healthy postmenopausal women, raloxifene and estrogen monotherapy have similar beneficial effects on low density lipoprotein cholesterol and fibrinogen levels. These treatments differ, however, in their effects on high density lipoprotein cholesterol, triglycerides, and plasminogen activator inhibitor-1 and possibly in their effects on prothrombin fragment F1+2 and C-reactive protein
- …